Logo

British Columbia Secures Reimbursement of Three New Biosimilars for the Prevention of Blood Clot

Share this
British Columbia Secures Reimbursement of Three New Biosimilars for the Prevention of Blood Clot

British Columbia Secures Reimbursement of Three New Biosimilars for the Prevention of Blood Clot

Shots:

  • British Columbia’s Ministry of Health has reported the 3 new enoxaparin biosimilars i.e., Redesca was developed by Valero, Noromby by Juno & Inclunox by Sandoz for the prevention of blood clot disorders
  • The 3 biosimilars secured public reimbursement status in British Columbia covered by PharmaCare which was the province’s public health plan while enoxaparin has been delisted. Additionally, both the original & high-potency versions of the products are available for public reimbursement
  • British Columbia has adopted its policy in Nov 2019 & moved into the third phase of the program in Aug 2020 including 3 rituximab biosimilars in its options list for patients  switched from Rituxan

Ref: The Center for Biosimilars | Source: Sandoz

Click here to­ read the full press release 

Neha

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions